Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
For more information about Lucid, please visit and for more information about its parent company PAVmed, please visit .NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024 at 1:30 p.m. ET.
紐約，2024年11月18日 /美通社/ -- Lucid Diagnostics Inc. (納斯達克: LUCD)（"Lucid"或「公司」），一家商業階段的癌症預防醫療診斷公司，以及PAVmed Inc.（納斯達克: PAVM）的子公司，今天宣佈公司管理層將於2024年11月21日星期四下午1:30（東部時間）在紐約的Canaccord Genuity醫療技術、診斷和互聯網醫療及服務論壇上進行演講。
Live and replay webcasts may be accessed on the investor relations section of the Company's website at ir.luciddx.com. The webcast will be archived and available for replay for at least 30 days after the event.
公司網站ir.luciddx.com的投資者關係部分可以訪問現場直播和重播網絡廣播。該網絡廣播將在活動後至少保留30天以供重播。
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
關於Lucid Diagnostics
Lucid Diagnostics Inc.是一家商業化階段的癌症預防醫療診斷公司，是PAVmed Inc.（納斯達克: pavmed）的子公司。Lucid專注於患有胃食管逆流病（GERD）的數百萬患者，他們有患食管癌前病變和癌症的風險，也被稱爲慢性胃灼熱。Lucid的EsoGuard食管DNA檢測，使用其EsoCheck食管細胞收集設備在簡短、無創的辦公室程序中收集樣本，代表了第一款也是唯一一款商業上可用的旨在通過廣泛的早期檢測預防癌症和癌症死亡的工具，用於在有風險的患者中檢測食管癌前病變。
For more information about Lucid, please visit and for more information about its parent company PAVmed, please visit .
欲了解有關Lucid的更多信息，請訪問 。欲了解其母公司PAVmed的更多信息，請訪問 。
SOURCE Lucid Diagnostics
來源：Lucid Diagnostics
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
